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ABSTRACT 
 
The objective of this paper is to study the effectiveness if the new method of breast 
cancer therapy, which is the application transdermal patch for the drug delivery system 
through the largest organ of human body, the skin. This study was done by simulating 
the process of drug diffusion using multiphysics software, COMSOL. For this study, we 
are using two types of drugs which have different physical and chemical properties as 
the subject, which is Paclitaxel and Doxorubicin. The simulation are done by obtaining 
the information such as the molecular weight and specific diffusivity of drugs through 
breast tissue until it reaches the targeted cancerous area. The simulation is computed 
using multiphysics software- COMSOL, to see how fast the drugs will be delivered to 
the targeted cancer cell. The effectiveness of this method of therapy by is studied by 
manipulating the properties of the type of drugs, the diffusivity of the drugs and the 
volume of the breast modeling. All of these parameters are manipulated by designing 
mathematical models governed by Fick‟s Law of diffusion. The differences of the 
concentration of drug on specific depth of breast tissue are shown by a color spectrum 
after the simulation was done. The application of transdermal patch in breast cancer 
therapy is the new type of drugs delivery system which lately has been the subjects of 
numerous researches, as it has been proven to be more advantageous than normal 
chemotherapy. The dosage of drug needs to be taken by the patients can be reduced 
significantly as this system is more topical and it is very specific, as the drugs applied to 
the skin will be absorbed and straightly attack the targeted cancer cell. Compared to 
normal chemotherapy, the drug pathway does not go through the vascular system or 
bloodstream, and it can reduce the side effects brought about by the strong drugs to the 
body of the patients. By doing this study, further development of this new type of breast 
cancer therapy can be done, so it can be creates more understanding and optimized as 
the primary type of breast cancer therapy. 
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ABSTRAK 
 
Objektif utama kajian ini adalah untuk mengkaji keberkesanan cara terapi baru untuk 
pesakit barah payudara, iaitu dengan menggunakan pelekat transderma sebagai ejen 
penghantaran dadah melalui organ terbesar pada tubuh manusia, iaitu kulit. Kajian ini 
dijalankan dengan mensimulasikan proses resapan dadah dengan mengunakan perisian 
multi fizik, iaitu COMSOL. Kajian ini akan bertumpu kepada dua jenis dadah yang 
digunakan untuk terapi barah payudara, dengan sifiat kimia dan fizikal yang berbeza 
antara satu sama lain, iaitu Doxorubicin dan Paclitaxel. Bagi menjalankan simulasi ini, 
sifat fizikal yang penting untuk dadah tersebut, iaitu jisim molekular relatif dan juga 
kadar resapan dadah melalui tisu payudara ke kawasan kanser diperolehi dari dari kajian 
terdahulu. Simulasi yang dijalankan menggunakan perisian COMSOL ini adalah untuk 
mengkaji masa yang diambil oleh sesuatu dadah untuk tiba ke kawasan sel kanser. 
Kadar keberkesanan cara terapi ini dikaji dengan memanipulasikan ciri-ciri seprti jenis 
dadah yang digunakan, kadar resapan dadah serta isipadu model payudara. Ciri-ciri ini 
akan dimanipulasikan dengan merekabentuk model matematik berdasarkan Fick’s Law 
of Diffusion. Kadar kepekatan dadah yang terdapat pada kedalaman spesifik didalam 
tisu payudara pada satu-satu masa akan diwakili oleh spektrum warna yang berbeza 
setelah melalui simulasi ini. Penggunaan pelekat transderma sebagai satu medium 
penghantaran dadah yang baru untuk terapi barah payudara akhir-akhir ini telah menjadi 
topik utama dalam kajian-kajian saintifik, kerana keupayaan dan keberkesanannya 
berbanding rawatan kemoterapi biasa. Dos ubat yang perlu diambil oleh pesakit-pesakit 
barah dapat dikurangkan, kerana sistem ini lebih bertumpu kepada kawasan kanser dan 
amat spesifik, kerana dadah yang dihantar menerusi kulit akan terus menuju ke kawasan 
yang telah dikenalpasti. Berbanding dengan rawatan kemoterapi, dadah itu tidak akan 
melalaui sistem vaskular mahupun sistem peredaran darah, dan akan mengurangkan 
kesan sampingan dadah tersebut kepada tubuh pesakit. Diharap dengan kajian ini, kajian 
bekenaan tentang sistem rawatan baru ini dapat diteruskan, agar ia lebih difahami dan 
dapat dioptimumkan keberkesanannya di masa akan datang. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
This chapter will provide the brief overview of breast cancer, the conventional 
therapy of breast cancer, and also the application of transdermal patch as the method of 
breast cancer therapy. This chapter will also go through the background of the study, the 
statement of problem for this research, objectives that want to be achieved from this 
study, the scope of study and also the rational and significances of this study to the 
scientific and commercial development.   
 
1.1 Background of study 
 
Breast cancer is one of the leading causes of death among women in the world. 
From the research done by The National Cancer Institute of United States of America, 
by the age of 50 years old, 1 out of 5 women will develop breast cancer. In Malaysia, the 
number of women affected by this disease increases from time to time. Although this 
disease is very dangerous, it is actually a highly treatable if it is detected in the early 
stage of the cancer.  
 
There are numerous ways that has been developed in order to treat the breast 
cancer patients, and some of the treatment are surgical treatment, therapy of very strong 
drugs, or is known as chemotherapy, and also hormonal therapy. The most drastic 
treatment for breast cancer is through mastectomy, or breast surgery. This approach is 
considered as the most efficient as it directly discard the tumor, but risk of the cancer to  
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return is still present and the procedure could leave physical trauma and effect to 
the patient. 
 
The most widely used method of therapy for breast cancer is using strong drug or 
chemotherapy. Traditionally, this method is done either by using shot injection, or by 
using oral drugs. The newest development in chemotherapy is application of transdermal 
patch, which is an adhesive patch containing the drugs that are applied to the skin, near 
the targeted breast cancer cell. The drugs will be absorbed by the skin, through the 
layers of breast tissue, until it reaches the specific region where the cancer cells lies. 
This study will simulate the effectiveness of different type of drugs used on the 
transdermal patch to the breast cancer by analyzing its concentration on different depth 
of breast for a specific time.  
 
1.2  Problem Statement 
 
The efficiency of the used of transdermal patch on the skin for breast cancer 
treatment rely upon the diffusivity of the drugs through layer of breast tissue, and also 
the chemical and physical properties of the drugs. The transportation of drugs through 
the skin is more effective than when it is taken orally or through injection, as the action 
is more topical and site specific. This study will focus on the use of two different types 
of drugs, which are Doxorubicin and Paclitaxel. These two drugs have different 
molecular weight and standard diffusivity, and this study will simulate the diffusion of 
these drugs in order to analyze its effectiveness. The drug diffusivity factors will also be 
examined in the simulation, where the drugs diffusivity will be manipulated to obtain 
the most effective drug diffusivity. Furthermore, the relationship between the breast 
volume and the efficiency of the treatment is studied. In order to analyze the 
effectiveness of the drug diffusion, we will simulates the diffusion process using, a 
multiphysics software, called COMSOL.  
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1.3  Research Objectives 
 
The main aim of this study is investigating the effectiveness of different type of 
drugs used on the transdermal patch to the targeted cancer cell. We also want to see how 
different type parameter affected this type of treatment. This can be achieved by 
fulfilling these objectives: 
 
1. To compare the effect of diffusivity of different type of drug used on the 
transdermal patch to the targeted cancer cell. 
2. To investigate the effect of the specific drug diffusivity to the efficiency of 
transdermal drug delivery system.   
3. To investigate the relationship between the breast volume and the 
concentration of drugs on the tissue  
 
1.4  Scope of Studies 
 
This study will focus on the effect of the diffusivity of two different kinds of 
drugs- Doxorubicin and Paclitaxel- and their efficiency on the treatment of breast 
cancer. The other parameter that we want to investigate in this study is the effectiveness 
of the usage of transdermal patch analyzing the specific diffusivity of the drugs used, in 
order to obtain the most efficient drugs diffusivity. The different breast model with 
different volume will also be designed in order to obtain the relationship between the 
breast volume and the efficiency of the treatment. To start this study, we will first obtain 
the data of the respective drugs, which are the specific diffusivity and the molecular 
weight of the drugs. The size of the breast will also be calculated to determine the 
placement of the patch on the breast and also to determine the volume of the breast. 
When all of this data was obtained, the mathematical model of the simulation will be 
constructed, and the simulation was run using multi-physics software- COMSOL. By 
using this software, the graph of the concentration of drugs through the breast on 
specific time will be obtained and analyzed.  
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1.5  Rational and Significance of Studies 
 
The rational of this study is provide additional insight to the treatment of breast 
cancer using transdermal patch as it is still considered a new development in healthcare. 
This method has been proven to be advantageous, comparing to the traditional 
chemotherapy method. This technology has been proven safer to the body because it did 
not affect the other tissue of the body aside from the targeted cancer cell, compared to 
oral drugs or shot injection, as it diffuse through the skin and did not go through the 
vascular system.  The better understanding of transdermal patch can optimize the 
concentration of the drugs used and the efficiency of the patch itself. This optimization 
can decrease the dosage of drugs for cancer treatment, thus reducing the cost of the 
treatment and making it more affordable.  
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
This chapter will cover about the overview of the statistics of the global and 
local breast cancer cases, the conventional treatment of breast cancer which includes 
physical surgery, the chemotherapy using strong drugs and hormonal therapy, and also 
the general principal of the application of transdermal patch for breast cancer therapy. 
 
2.1  Overview of Breast Cancer Cases 
 
Cancer has become one of most prominent cause of death to globally, especially 
in the developed nation. The main reason on why cancer continues to develop such a 
dangerous reputation as the big killer is because of the aging and growth of the world 
population alongside an increasing adoption of cancer-causing behaviors, particularly 
smoking, in economically developing countries.  
 
Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 
7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the 
cases and 64% of the deaths occurred in the economically developing world. Based on 
these data, it was also found that the leading cancer that affects women in the world is 
breast cancer.  
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Figure 2.1: Distribution of cancer among women globally (top) and locally (bottom) 
 
Source: National Cancer Registry (2008) 
 
Nearly 70,000 new cancer cases were diagnosed among Malaysians in 
Peninsular Malaysia between 2003 and 2005, according to a report released in early 
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2008 on the incidence of the disease in West Malaysia. The Cancer Incidence in 
Peninsular Malaysia 2003-2005 report, published by the National Cancer Registry 
(NCR), states that the total 67,792 new cases were diagnosed among 29,596 males (43.7 
per cent) and 38,196 females (56.3 per cent). The annual crude rate for males was 100.2 
per cent per 100,000 population, and 132.1 per cent per 100,000 for females. The most 
frequent cancer Malaysians was breast cancer (18 per cent) followed by large bowel 
cancer (11.9 per cent) and lung cancer (7.4 per cent). 
 
There were 3825 cases reported and 1707 death from breast cancer in Malaysia 
(Globocan, 2000). They estimated that among 100,000 populations, the crude rate of 
breast cancer in Malaysia is 34.9 with Age Standardised rate of 41.9 per 100,000. From 
2003-2005, breast cancer formed 31.1% of newly diagnosed cancer cases in women, up 
1.1% from 2002.  
 
Figure 2.2: Percentage of breast cancer in Malaysia 2002-2003 
 
Source: College of Radiology Breast Health Information Centre (2008) 
 
Breast cancer is not a topical disease that can only affect certain population, the 
fact that it can kill anyone is very worrying. The National Cancer Institute of America 
estimated that by the age of 50, one out of 50 women is affected by breast cancer. This 
number will rise to ten when they reach 80 years old. Over the years from 1993 to 2003, 
there were a total of 1818 breast cancer patients in the University Hospital. The number 
of breast cancer patients increased annually, with the highest recorded in 2003. This was 
6 times the number of breast cancer patients in 1993. 
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2.2  Conventional breast cancer treatment 
 
The development in breast cancer treatment has brought about several ways in 
order to treat this disease. Some of the method that has been used to treat breast cancer 
is through breast surgery, chemotherapy of strong drugs, and also hormonal therapy.  
 
2.2.1  Breast surgery 
 
Surgery treatment for breast cancer can be divided into two - mastectomy and 
breast conserving surgery. Mastectomy is the method where the breast structure will be 
removed in order to remove the cancer cells. For breast conserving technology, it 
requires more advanced technology, where the cancer cell will be removed using 
sentinel node biopsy, complimented with radiation. This method allowed women with 
different form of breast cancer to conserve their breast (Apantaku, 2002). 
 
 Study shows that survival rate after breast conserving technology complimented 
with radiation are equal to the survival rate after mastectomy for stage 1 and 2 breast 
cancer (Winchester, 1998). Although both method of surgery has been proven to be 
reliable for cancer patients, mastectomy remains the most common treatment for women 
with invasive tumor or treatment for early stage of cancer (Morrow et. al., 2001).  
 
The type of surgery that is suitable for the patient depends on the size of the 
cancer in the breast, whether it has spread to any other part of the body, the size of the 
breasts and personal wish (CancerHelp UK). According to Opatt et. al., due to lack of 
knowledge about the option, the patients are not aware with the choices that they have, 
and still choosing the widely known mastectomy technique, although there are better 
choices for them. 
  
From the research done by International Breast Cancer Intervention Study (IBIS) 
in 2002, the women who are eligible for breast cancer surgery are those with high risk 
benign lesion, which are: 
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1. Lobular Neoplasia (lobular carcinoma in-situ) 
2. Ductal hiperplasia/ atypical lobular hiperplasia 
3. Multiple papillomatosis 
4. Some type of proliferative fibrocystic mastophaty 
5. Primary breast phylloide tumor and relapses. 
 
Recommended surgical care for invasive breast cancer includes removal of the 
primary tumor and a level I and II axillary lymph node dissection (ALND). The status of 
the axillary nodes helps to determine the prognosis and guide treatment decisions. 
Unfortunately, side effects after ALND are relatively common. Some of the effects of 
ALND are: 
 Upper-extremity 
 Lymphedema (6%-49%),  
 Arm numbness/tingling (7%-75%) 
 Pain (16%-56%),  
 Impaired shoulder mobility (4%-45%),  
 Arm weakness (19%-35%),  
  Infections in the breast, chest, or arm (8%). 
(Kakuda et al,1999 and Petrek et al, 2001)  
 
The side effects of axillary lymph node dissection can range from mild to severe 
and can be a chronic condition that affects patients' quality of life for years after cancer 
surgery (Maunsell et al, 1993). 
 
Recently, a less invasive procedure, sentinel lymph node dissection (SLND), has 
been developed to stage the axilla for invasive breast cancer. This technique is 
performed by using a blue dye and a radioactive tracer injected into the breast tissue. 
SLNs are removed during the surgical procedure, and the pathology results from these 
nodes have been found to be highly predictive of metastatic involvement in the axilla 
(Albertini et al, 1996). As a result, SLND has become an acceptable alternative to 
ALND for patients with clinically negative lymph nodes. 
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Treatment of cancer using surgery can cause physical alteration and emotional 
trauma to the patients. Most of the patients that undergo mastectomy will need 
reconstruction for the breast structure. Because surgery is not a safe method, complex 
and often does not give satisfactory result, it is difficult to accept it as preventive method 
for breast cancer (Diaz-Faes, 2003). 
 
2.2.2  Chemotherapy 
 
The most common type of breast cancer therapy, chemotherapy, in its simplest 
sense, is a therapy by ingestion of strong drugs, either orally or through injection, where 
the drugs will attack the targeted cancer cells and kill it. The main principal of the 
growth of invasive tumor depends on angiogenesis, which is the formation of blood 
vessels that will provide the tumor with nourishment and nutrients (Folkman, 1990). 
Because of this feature, the chemotherapy was designed so that the drugs can pass 
through the blood vessels to reach the targeted cell and attacking the tumor.  
 
Most popular chemotherapy agents like taxanes and anthracyclines has distinct 
anti-angiogenic activity (Miller et. al., 2001), while others such as doxorubicin can 
inhibit collagenase of the cancer cells, preventing it from dividing and stop the growth 
(Benbow et. al., 1999). Although this method is widely used and has been proven 
effective, it can cause severe side effects to the patients. The drugs, which were taken 
orally or through injection, will be distributed to the entire body affecting other rapidly 
dividing cells, such as hair follicles, nails, mouth and bone marrow as it do not have the 
ability to distinguish between normal and tumor cells.  
 
Docetaxel and doxorubicin, two widely used drugs for cancer treatment, cause 
significant drop of blood cell in patients‟ bone marrow, increasing their risk of getting 
an infection (Cancer Health UK, 2009). The drop in red blood cell can cause fatigue and 
breathlessness, while drop in platelets contributes to bruising. Some drugs, like 
letrozole, caused the depletion of circulating estrogen, causing the patients to experience 
hot flashes and suffer from bone damage in a long time (Mom et. al., 2006). Letrozole 
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which were taken by oral capsule is difficult to be administered the right dosage that 
suitable for the body (Li et. al., 2010) 
 
2.2.2.1  Docetaxel 
 
Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared 
by semisynthesis beginning with a precursor extracted from the renewable needle 
biomass of yew plants. The chemical name for docetaxel (anhydrous) is (2R,3S)-N-
carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5β-20epoxy-
1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate. Docetaxel 
(anhydrous) has the following structural formula: 
 
Figure 2.3: Structure of Docetaxel 
 
Source: Drugbank (2005) 
 
Docetaxel kills cells by disrupting the function of microtubules, which are 
essential for cell survival (Shelley et al.,2007). It also inhibits the anti-apoptotic gene 
Bcl2 and encourages expression of p27, a cell-cycle inhibitor (Van Poppel, 2005), 
preventing new cells from forming, and causes existing cells to undergo apoptosis and 
stops other cells from maturing and replicating. As with all cytotoxic agents, the effect 
of the drug is not specifically aimed at the tumour cells, so „healthy‟, normal cells may 
be affected too, resulting in drug-related side effects. 
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Docetaxel-containing treatment regimens that is potentially associated with a 
20% or greater risk of febrile neutropenia. The incidence of treatment-related mortality 
associated with docetaxel therapy is increased in patients with abnormal liver function, 
in patients receiving higher doses, and in patients with non-small cell lung carcinoma 
and a history of prior treatment with platinum-based chemotherapy who receive 
docetaxel as a single agent at a dose of 100 mg/m². Baker (1999), has also outline some 
non-haematological toxicity effect to the patients, such as hypersensitivity reaction, fluid 
retention, nail toxicity and neuropathy effect. 
 
2.2.2.2  Doxorubicin  
 
Doxorubicin is an anthracycline topoisomerase inhibitor isolated from 
Streptomyces peucetius var. caesius. Doxorubicin HCl, which is the established name 
for (8S,10S)– 10- [(3– amino - 2,3,6– trideoxyαL– lyxo- hexopyranosyl) oxy]– 8- 
glycolyl- 7,8,9,10- tetrahydro- 6,8,11 trihydroxy- 1- methoxy 5,12- naphthacenedione 
hydrochloride, has the following structure: 
 
Figure 2.4: Structure of Doxorubicin 
 
Source: Drugbank (2005) 
 
It is a common drugs used in the breast cancer therapy, which work as an  
anthracycline antibiotic, closely related to the natural product daunomycin, and like all 
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anthracyclines, it works by intercalating DNA, which inhibits the progression of the 
enzyme topoisomerase II, that relaxes supercoils in DNA for transcription. Doxorubicin 
stabilizes the topoisomerase II complex after it has broken the DNA chain for 
replication, preventing the DNA double helix from being resealed and thereby stopping 
the process of replication. The formula is C27H29NO11
 
, and the molecular weight is 
543.52 g/mol. 
 
The use of doxorubicin may lead to cardiac toxicity. Myocardial damage may 
lead to congestive heart failure and may occur as the total cumulative dose of 
doxorubicin HCl approaches 550 mg/m². Acute infusion-related reactions including, but 
not limited to, flushing, shortness of breath, facial swelling, headache, chills, back pain, 
tightness in the chest or throat, and/or hypotension have occurred in up to 10% of 
patients treated with doxorubicin. 
 
The acute effects are mainly myelo-suppression, nausea, vomiting, weight loss, 
arrhythmias and decreased survival, whereas the main chronic effect of doxorubicin is 
severe cardiomyopathy with precipitant congestive heart failure (Olson et al, 2007). 
  
2.2.2.3  Herceptin 
 
Herceptin is a humanized IgGl kappa monoclonal antibody that selectively binds 
with high affinity to the extracellular domain of the human epidermal growth factor 
receptor 2 protein, HER2. Herceptin is produced by recombinant DNA technology in a 
mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. 
Gentamicin is not detectable in the final product. The important chemical data for 
herceptin is the chemical formula, which is C6470H10012N1726O2013S42, and the molecular 
weight is 145531.5 g/mol. 
 
Herceptin administration can result in sub clinical and clinical cardiac failure. 
The incidence and severity was highest in patients receiving herceptin with 
anthracycline containing chemotherapy regimens. The treatment of breast cancer using 
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herceptin can also result in serious and fatal infusion reactions and pulmonary toxicity. 
Symptoms usually occur during or within 24 hours of the treatment with herceptin. 
 
2.2.3  Hormonal therapy 
 
Women hormones, oestrogen and progesterone, can trigger the growth of some 
cancer cells. Oestrogens exert a large variety of responses in target cells, including 
promotion of tissue differentiation, morphogenesis, mitogenic activity and development 
of the mammary gland, which us very beneficial to the general function of human body. 
However, aside from their essential function in female reproduction, it is also 
responsible in oncogenesis and maintenance of tumor growth (Ameller et al). In fact, 
oestrogens are regulators of a number of proto-oncogenes coding for nuclear proteins. 
Oestrogens act on cells via interaction with two types of intracellular receptors. 
Eventually, the recent discovery of ER has greatly enhanced our understanding of 
oestrogen action. 
 
The used of hormonal therapy in breast cancer treatment are done in order to 
lower the level of these hormones and/or block their effect. The goal of the therapy is to 
develop anti-oestrogens, compounds capable of blocking the effects of estradiol (E2) 
without displaying any oestrogenic activity on their own. 
   
Hormone therapy can be done either before or after the surgery, or to treat 
relapses, which is breast cancer that comes back after the surgery (CancerHelp UK). 
Hormonal therapy is considered as one of the better treatment of cancer as it does match 
chemotherapy in terms of survival and tumor response. In addition, hormonal therapies 
produce fewer and less severe adverse effects than chemotherapy (Jordan, 2002) 
 
Patients‟ response to hormonal therapy depends on their hormone receptor status 
– estrogen receptor positive (ER+) or progesteron receptor positive (PgR+). Higher 
response to it brought a greater likelihood to response to the treatment (Osborne et. al., 
1980). Approximately 50% to 70% of women benefit from hormonal therapy if their 
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tumors are positive for both ER and PgR, 33% benefit if their tumors are positive for 
either type of receptor, and only 11% benefit if their tumors are negative for both types. 
  
There are several therapies that have been developed regarding hormonal therapy 
for breast cancer, which are including the selective estrogen receptor modulators 
(SERMs), aromatase inhibitors (AIs), and estrogen receptor (ER) antagonists. 
 
2.2.3.1  Selective Estrogen Receptor Modulators (SERMs) 
 
The first type of hormonal therapy for breast cancer is Selective Estrogen 
Receptor Modulators (SERMs). The drugs used for this treatment can mimic the action 
of estrogen in the body, and modulating the estrogen receptor. The most popular drugs 
that is used in hormonal therapy for breast cancer treatment is Tamoxifen, which is 
considered the gold standard of the procedure since 1970‟s. Other drug that has similar 
function with Tamoxifen is Toremifene. 
  
Some of the adverse effects between Tamoxifen and Toremifene is similar, 
which are hot flashes, nausea, vomiting and vaginal discharge. Tamoxifen, however, 
was associated with a higher incidence of thromboembolic events (1.3%- 8.0% vs 0.6%-
5.1%), vaginal bleeding (0%-19.8% vs 0.9%-3.7%), and endometrial cancer (0%-1.8% 
vs 0%) compared with toremifene (Cummings, 2002) 
 
This drug usually recommended to be taken for five years usage, as the used of it 
longer than five years did not further the benefits, instead it increase dangerous side 
effects such as blood clots within deep veins (pulmonary embolism), endometrial cancer 
and stroke. 
  
2.2.3.2  Aromatase Inhibitors (AI) 
 
Aromatase inhibitors stop the production of estrogen in post-menopausal 
women. Aromatase inhibitors work by blocking the enzyme aromatase, which turns the 
